1. Home
  2. RIGL vs DFDV Comparison

RIGL vs DFDV Comparison

Compare RIGL & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • DFDV
  • Stock Information
  • Founded
  • RIGL 1996
  • DFDV 2018
  • Country
  • RIGL United States
  • DFDV United States
  • Employees
  • RIGL N/A
  • DFDV N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • DFDV Finance: Consumer Services
  • Sector
  • RIGL Health Care
  • DFDV Finance
  • Exchange
  • RIGL Nasdaq
  • DFDV Nasdaq
  • Market Cap
  • RIGL 335.5M
  • DFDV 330.2M
  • IPO Year
  • RIGL 2000
  • DFDV N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • DFDV $16.02
  • Analyst Decision
  • RIGL Buy
  • DFDV Buy
  • Analyst Count
  • RIGL 5
  • DFDV 1
  • Target Price
  • RIGL $38.20
  • DFDV $45.00
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • DFDV 3.5M
  • Earning Date
  • RIGL 08-05-2025
  • DFDV 08-12-2025
  • Dividend Yield
  • RIGL N/A
  • DFDV N/A
  • EPS Growth
  • RIGL N/A
  • DFDV N/A
  • EPS
  • RIGL 5.43
  • DFDV 1.17
  • Revenue
  • RIGL $267,921,000.00
  • DFDV $3,520,660.00
  • Revenue This Year
  • RIGL $59.93
  • DFDV $70.03
  • Revenue Next Year
  • RIGL N/A
  • DFDV $142.86
  • P/E Ratio
  • RIGL $7.15
  • DFDV $13.67
  • Revenue Growth
  • RIGL 105.62
  • DFDV 97.13
  • 52 Week Low
  • RIGL $12.66
  • DFDV $0.49
  • 52 Week High
  • RIGL $43.72
  • DFDV $53.88
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • DFDV 46.25
  • Support Level
  • RIGL $39.00
  • DFDV $15.23
  • Resistance Level
  • RIGL $42.08
  • DFDV $20.30
  • Average True Range (ATR)
  • RIGL 2.32
  • DFDV 2.30
  • MACD
  • RIGL -0.37
  • DFDV 0.08
  • Stochastic Oscillator
  • RIGL 53.26
  • DFDV 19.72

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About DFDV DeFi Development Corp. Common Stock

DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.

Share on Social Networks: